A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Acne Vulgaris

• Status: Not yet recruiting
• Trial end date: 2022-10-15
• Target enrollment: 0
• Participant gender: All

Summary

Efficacy and Safety of Imsidolimab in Subjects with Acne Vulgaris

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AnaptysBio, Inc.

Criteria

Inclusion Criteria:

• Diagnosis of moderate to sever facial acne vulgaris

• Facial IGA score of 3 (moderate) or 4 (severe)

• At least 20 and no more than 100 inflammatory lesions on the face

• No more than 100 noninflammatory lesions on the face.

• No more than 5 nodules (≥5 mm) on the face

Exclusion Criteria:

• A subject with acne fulminans or conglobate or secondary acne will be excluded.